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Abstract: This viewpoint is a global call to promote fundamental and applied research aiming
toward designing smart nanocarriers of desired properties, novel noninvasive strategies to open
the blood–brain barrier (BBB), delivery/release of single/multiple therapeutic agents across
the BBB to eradicate neurohuman immunodeficiency virus (HIV), strategies for on-demand
site-specific release of antiretroviral therapy, developing novel nanoformulations capable
to recognize and eradicate latently infected HIV reservoirs, and developing novel smart
analytical diagnostic tools to detect and monitor HIV infection. Thus, investigation of novel
nanoformulations, methodologies for site-specific delivery/release, analytical methods, and
diagnostic tools would be of high significance to eradicate and monitor neuroacquired immunodeficiency syndrome. Overall, these developments will certainly help to develop personalized
nanomedicines to cure HIV and to develop smart HIV-monitoring analytical systems for disease
management.
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Human immunodeficiency virus (HIV) is a deadly infectious disease and has
been declared as a serious concern worldwide.1–3 The World Health Organization
confirms .35 million HIV-infected people. Among them, 28 million people are eligible
for antiretroviral therapy (ART). However, only 11.7 million could afford antiretroviral
(ARV) drugs. In spite of significant advances in highly active ART, the elimination
of HIV-1 reservoirs from the peripheral nervous system and central nervous system
(CNS) remains an ultimate challenge.4 This is attributed to the integration of HIV-1
genome with host genome, thereby causing viral latency in the periphery and in brain,
as well. Furthermore, the inability of ART to penetrate the blood–brain barrier (BBB)
after systemic administration makes brain as one of the most dominant HIV infection
reservoirs.1 Developing the best suitable therapeutics for HIV demands multidisciplinary research and development approaches involving smart sensors, novel imaging
agents, smart portable diagnostic tools, biomarkers, novel bioimaging, efficient affinity
agents, smart assaying, real-time disease monitoring, and disease management systems
to develop accessible cost-effective diagnosis and treatment for HIV patients.1
Advancements in analysis have proven a significant role in HIV diagnostics
and monitoring of disease progression. The US Food and Drug Administration
approved ~38 various anti-HIV drugs. The therapeutic effects of these drugs have been
studied using advanced analytical tools and methods. In the present scenario, appreciated efforts have been made to explore effective dual antiviral drugs and long-acting
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(LA) drugs and vaccines to eradicate HIV infection without
adverse effects. Recently, dual therapy, ie, an optimized
cocktail of two ARV drugs, has been explored to manage HIV
infection. A comprehensive review on the effects, advantages,
and disadvantages of the dual therapy is described by Kelly
et al.5 The authors claimed that the dual therapy containing
tenofovir (Tef) exhibited more therapeutic advantages than
triple therapy. However, the selection of appropriate drug
according to the patient condition is very crucial because this
therapy may reduce virologic efficacy in HIV-infected patient
while lowering CD4 counts per high pre-ART HIV-1 RNA
level. This report proposed that new nanoformulations (NFs)
of LA cabotegravir (Ctg) and rilpivirine (Rpv) may have
bright future prospects for HIV therapeutics. Such a viable
dual therapy is useful to manage ART options and performance, which lowers the costs and the globally unmet needs
of pill-fatigued and adherence-challenged individuals.5
LA drugs, as HIV therapeutic agents, are in practice for
HIV prevention due to their effective longer therapeutic
effects at a very low dose in comparison to daily consumption of ART. The strengths, weaknesses, opportunities,
and challenges of LA-injectable therapies for HIV have
been described excellently by Owen and Rannard. 6 The
pharmacology and formulation of LA Ctg were described
in a comprehensive review presented by Trezza et al.7 The
authors concluded that the pharmacologic profile of Ctg has
great potential for the treatment and prevention of HIV-1
infection. This drug exhibited half-life of 40 days and
showed therapeutic action at a low dose. Thus, monthly and
bimonthly oral administration in the form of tablet would
be enough to control HIV infection.7 The multi-component
pharmacokinetic evaluation of LA Rpv, 300 mg, 600 mg, or
1,200 mg (for 84 days), in 66 HIV-negative volunteers for
preexposure prophylaxis was performed by Jackson et al.8
The authors assessed ex vivo antiviral activity of cervicovaginal lavage and claimed that each Rpv dose exhibited effective therapeutic effect, lasting till 84 days, upon exposure to
plasma and genital tract. This study is useful to decide the
appropriate dose for HIV therapeutics.8 In another study,
the safety, tolerance, and pharmacokinetics of LA Rpv
(TMC278, 300 mg/mL) formulation on administration, single
and multiple intramuscular injection, in healthy volunteers
were assessed by Verloes et al.9 The outcomes of this study
suggested that a clinically relevant plasma concentration of
Rpv could be optimized via tuning LA formulation.9 Very
recently, Margolis et al10 presented a multicenter study based
on long-acting ARV treatment enabling trial, for Phase IIb,
using HIV-infected adults (.18 years old). The results
suggested that Ctg plus dual nucleoside reverse transcriptase
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inhibitors (NRTIs) therapy exhibited antiviral activity and
Ctg (30 mg, once a day) plus Rpv (25 mg, once a day)
also exhibited 96 weeks longer antiviral activity similar to
efavirenz plus NRTIs. The authors claimed that the injectable formulation of Rpv plus Ctg can be used as a two-drug
regimen for HIV infection therapeutics.10
Besides significant advancements in ARV drug development for HIV therapeutics, very few efforts were made
to develop an effective anti-HIV vaccine. Gautam et al11
demonstrated the long-term efficacy and protection evaluation of passively transferred four anti-HIV-1-neutralizing
monoclonal antibodies (VRC01, VRC01-LS, 3BNC117,
and 10-1074), with a single high dose (20 mg/kg), in an
HIV-infected monkey model. The authors claimed that a
specific single neutralizing antibody demonstrated virus
reduction up to 23 days. The results of this study suggested
that all four antibodies showed plasma-neutralizing efficacy,
which is dependent on antibody potency and half-life. Based
on the outcomes, a specific anti-HIV antibody could be
selected and injected to control high-risk transmission of HIV
infection.11 To avoid the adverse effects of multitherapeutic
agents, efforts are being made to design novel therapeutic
agents that could work singly for activation and eradication
of HIV infection. Guided genes, ie, CRISPR–Cas9/gRNA
system, are recently being investigated to eradicate HIV in
latently infected HIV reservoirs.3,12,13 Unfortunately, these
studies were performed either in vitro or in periphery. HIVinfected and latently infected HIV brain reservoirs could not
be targeted due to negligible transmigration of therapeutics
against HIV across the BBB.2 Therefore, efforts should be
made to explore novel analytical science and nanotechnology
for developing strategies to deliver therapeutics across the
BBB to prevent neuroacquired immunodeficiency syndrome
(neuroAIDS) in the brain.14
The major challenge to cure neuroHIV is the inability
of effective anti-HIV therapeutic agents to cross the complex integrity of the BBB. This makes HIV, ie, neuroHIV,
incurable in the brain. Specific receptor binding,15,16 focused
ultrasound,17 microbubble-assisted focused ultrasound,18 and
magnetic field19-based approaches have been demonstrated
to open the BBB for delivery of therapeutic agent. Receptorfunctionalized therapeutic cargos are bigger in size and thus
affect efficacy, while an externally stimulated approach results
in transient BBB opening, which may also allow the delivery of
unwanted agents to the brain.20 Such agents, in the brain, may
cause additional neuroinflammation and associated dementia.
Recently, a noninvasive magnetically guided approach has
been demonstrated by Kaushik et al.20 In this approach, the
authors injected a biocompatible dose of magnetoelectric
International Journal of Nanomedicine 2016:11
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nanoparticles (MENPs; 10 mg/kg), potential drug nanocarriers
(NCs), into the mice brain via tail under a static magnetic field
(0 T) for 3 hours to achieve CNS delivery. The transmission
electron microscopy study conducted on the brain tissue
of mice showed uniform distribution of MENPs in all cell
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types without agglomeration (Figure 1). Hematoxylin and
eosin staining, blood toxicity assessment, and neurobehavior
evaluation studies confirmed that the adopted methods using
MENP are safe for living beings and also did not affect motor
coordination function of mice.20
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Figure 1 Illustration of MENP delivery to the brain under the influence of static magnetic field (A). Ex-vivo TEM image of brain tissue of control (B) and MENP-injected
(C) mice.
Notes: MENPs are capable of navigating across the BBB (Ba vs Ca); direction of movement across tight junctions of layers of E is indicated by arrows. MENPs are able to
reach target sites, including N, A, and M, and are also observed in S, E, and blood cells (☼). Most MENPs are uniformly distributed in the brain tissue/cells and are able to
reach nucleus (dotted circles), but some agglomeration of MENPs in cell membranes and their entrapment in endosomes are also observed (solid arrow heads). *Represents
synapses (Cc), J represents neuromuscular junction between S and the axon terminal (Ce). Scale bars: 1 µm (Ba; Ca, b, and e) and 0.5 µm (Bb; Cc, d, and f). Republished
from Kaushik A, Jayant RD, Nikkhah-Moshaie R, et al. Magnetically guided central nervous system delivery and toxicity evaluation of magneto-electric nanocarriers. Sci Rep.
2016;6:25309.20
Abbreviations: MENP, magnetoelectric nanoparticle; TEM, transmission electron microscopy; BBB, blood–brain barrier; E, endothelial cells; N, neurons; A, astrocytes;
M, microglia; S, smooth muscle cells; sc, Schwann cells; J, neuromuscular junction.
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The NCs of metal, metal oxides, gels, biopolymer,
composites, and core-shell nanostructures are being designed
and explored for binding of anti-HIV drugs and release of
stimuli responses.2,20,21 The successful release of binded drugs
is demonstrated in either a sustained or externally stimulated
on-demand controlled manner. At present, developed NFs, ie,
optimized combination of NCs and specific drug, were tested
using an in vitro model that exhibited a high therapeutic effect
and less adverse effect.1,21,22 Carson et al23 demonstrated a
tunable sustained release of multiclass water-soluble (hydrophilic) anti-HIV drugs, ie, Tef, using polyester-blended electrospun fibers as a potential drug NC.23 The authors claimed
that binding and release of anti-HIV drug was dependent
on the affinity level between Tef and the functional groups
available on the biocompatible fiber. This developed NF is
able to carry high drug loading, ~40 wt%, and demonstrated
sustained release from 24 hours to 30 days.23 However, this
in vitro model needs to be confirmed using an in vivo model
to evaluate the ability to cross the BBB. Destache et al24
developed an NF containing Tef to prevent HIV-1 vaginal
transmission in a humanized mouse model. The authors
formulated Tef disoproxil fumarate at the nanoscale using a
thermosensitive gel of poly(lactic-co-glycolic acid) prepared
using oil-in-water emulsification. The efficacy of this formulation was tested in humanized bone marrow–liver–thymus
mice. The results of this study suggested that Tef disoproxil
fumarate-NF acted as an LA drug via sustained release of
Tef to show coitus-independent HIV-1 vaginal protection
modality.24 Freeling et al25 developed an NF containing three
LA anti-HIV drugs (lopinavir, ritonavir, and Tef) loaded in a
lipid nanoparticle for longer exposure in primate plasma cells
within lymph nodes (persistent HIV reservoirs) and blood to
cure HIV infection. This developed NF showed 50-fold higher
intracellular drug concentration in lymph in comparison
to free drug administration. After single administration to
plasma, the authors demonstrated that the intracellular drug
level was enhanced until 7 days. Thus, the presented NF can
be used as oral therapy for HIV at the periphery level.25
Roy et al26 developed an NF (140 nm) to eradicate HIV
infection in the gut-associated lymphoid tissue (GALT), a reservoir of early HIV infection and host–pathogen interaction. The
complex physiology of GALT resisted delivery of conventional
anti-HIV drugs. Thus, developing NF specific to GALT is of
high therapeutic importance. The authors explored paracellular
transport property of M-cells for targeted delivery of pluronic
NCs containing anti-HIV drug (efavirenz) functionalized with
M-cell-specific antibody of the GALT. The sustained release of
anti-HIV drug significantly reduced the HIV infection level in
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the GALT, compared to the free drug.26 Recently, nanomedicine
technology has been explored to improve the efficacy of LA
Rpv via developing an NF for pericoital and coitus-independent
HIV infection therapeutics, demonstrated by Kovarova et al.27
In this research, the authors binded Rpv with poly(lactic-coglycolic acid) nanoparticles and encapsulated them with a
thermosensitive gel for delivery purpose. This NF, considered
as solid nanosuspension of LA Rpv, was administrated intramuscularly in the bone marrow–liver–thymus mice. A single
dose of this NF in mice, after a week, showed significant protection against high dose of vaginal challenge with HIV-1. The
authors claimed that sometime in the presence of the antiviral
drug, HIV infection may show systematic replication even on
sustained release of ARV. Thus, implication of LA Rpv for
HIV therapeutics is crucial and can be achieved by infecting
such developed LA Rpv-based NF.27
To manage HIV-1 infection in the brain, significant efforts
must be made to deliver this NF to the CNS. Numerous
reports confirm that navigation across the BBB depends on
the properties of NCs and NFs.1,2 Thus, exploring the properties of NCs and NFs independently is crucial to design an
effective therapeutic cargo to cure HIV completely in the
brain. However, the BBB always prevents the migration of
NCs to the brain. Surface science has explored making the
surface of NCs hydrophobic and generating functionality on
NCs to bind with the BBB-related specific biomolecules, such
as antibody, protein, and enzyme, to achieve CNS delivery.
Externally controlled navigation strategy based on magnetic
field and ultrasound strategy has recently been demonstrated
for transmigration of NCs across the BBB.1,2
Recently, magnetic nanoparticles (MNPs) have been
proposed as potential NCs to prepare effective NFs for the
eradication of HIV in the brain and periphery.4,21 Jayant et al4
developed layer-by-layer technology-based novel NFs consisting of tef, vorinostat (a latency-breaking agent), and
Fe3O4 (10±3 nm) as NCs for the treatment of neuroAIDS.
The authors demonstrated magnetically guided delivery of
this NF across the BBB and sustained release of both agents
to activate and then eradicate HIV infection. The outcomes
of this study suggested that loading and release of drug are
dependent on layer-by-layer formulation later. This would
help to monitor and control the pharmacokinetics. This NF
showed sustained release of therapeutic agent over a period of
5 days after HIV infection in primary human astrocytes, with
good cell viability (90%).4 Raymond et al28 demonstrated the
magnetically guided delivery of Nef peptides across the BBB
using MNPs as NCs to induce microglial cytokine/chemokine
secretion. The exNef is a novel mediator of HIV-induced
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neuropathogenesis and could be modulated in the presence
of Nef peptides. The successful delivery functionality of
Nef peptides in the CNS may be useful to develop novel
personalized nanomedicine for HIV therapeutics.28 Externally controlled on-demand controlled release of an NRTI,
3′-azido-3′-deoxythymidine-5′-triphosphate (AZTTP), an
anti-HIV drug, was demonstrated using MENPs as a potential
nanodrug carrier. An NF, consisting of MENPs and AZTTP,
was formulated and magnetically delivered across the BBB.29
An external alternating current (AC) magnetic field through an
electromagnetic coil was applied to release AZTTP from NF.
In this mechanism, MENPs showed polarization on AC
magnetic field stimulation, which changed the electrostatic
bond between MENPs and the bound drug. This phenomenon occurred rapidly and repeatedly, resulting in release
of the drug from the surface of MENPs. MENP-based NFs
were magnetically guided across the BBB, and 100% drug
release was achieved via tuning the frequency and applying AC magnetic field. This NF significantly eradicated
HIV-1 infection level across the BBB and has potential to
be tested using animal models.21,29 It is well known that
antiviral drug in CNS induces neuroinflammatory resulted
in neurotoxicity. Recently, magnetically guided delivery
of an anti-inflammatory agent, namely, tissue inhibitor of
metalloproteinase-1 (TIMP1), across the BBB is demonstrated to reduce HIV infection using MNPs as NCs and
SK-N-MC neuroblastoma cells as in vitro model.30 This
report claimed that TIMP1 reduced neuronal toxicity and
significant recovery of spinal density and thus confirmed
neuroprotective effects of TIMP1 in the CNS.30 The above
discussed in vitro model showed impressive reduction in the
HIV infection level across the BBB; therefore, efforts must
be made to demonstrate these models in vivo to develop
personalized nanomedicine to cure neuroHIV.
Besides successful in vitro demonstration, an NF, prepared using biocompatible nanogels binded with NRTIs, was
developed by Senanayake et al,31 and they claimed this NF
as a novel antiviral agent of high efficacy to combat against
HIV infection. This group developed a cationic nanogel, ie,
cholesteryl-ε-polylysine, to encapsulate NRTI 5-succinate
derivatives to evaluate anti-HIV activity using in vitro
microphage model in the CNS as well. This NF demonstrated
tenfold suppression in reverse transcriptase activity (EC90)
in HIV-infected macrophage in comparison to single/double/
triple drug cocktails recommended for clinical trials.31 The
sustained release of NRTIs for long time, enhanced efficacy,
and biocompatible nature proposed this NF as a promising
candidate to be tested in humanized mouse (hu-PBL) HIV
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model for the development of personalized nanomedicine.
Recent success in the CNS delivery of ARV, ie, zidovudine
(AZT), through the nasal route using chitosan microparticles
(CP), prepared by spray drying techniques, as a carrier to cure
brain HIV sanctuaries has been reported by Dalpiaz et al.32 The
authors produced a prodrug via conjugating AZT with ursodeoxycholic acid (UCDA–AZT) to overcome the issue of active
efflux transporter systems. The UCDA–AZT (5 µM or 10 µM)
system demonstrated 20 times higher efficacy than AZT to
cure HIV in the CNS and in macrophages.32 To demonstrate
delivery to rat brain, the authors administered this prodrugencapsulated CP through the nasal route, aiming to achieve
high CNS uptake. The results suggested that utilization of CP
increased the dissolution rate of UDCA–AZT and reduced
water uptake, resulting in high levels in cerebrospinal fluid in
rats, which is required for better efficacy in the CNS.32
Currently, scientists are exploring novel multi-functional
NFs to block unwanted disorders in HIV-infected patients
using substance of abuse.33 Sagar et al33 developed a highly
selective magnetic NF for the delivery of a therapeutic
agent to block the effects induced by morphine. A morphine
antagonist, ie, d-Pen-Cys-Tyr-DTrp-Orn-Thr-Pen-Thr-NH2
(CTOP), was bound with MNP and magnetically delivered
across the BBB. Over time, release of CTOP showed significant efficacy via protecting modulation of neuronal dendrite
and spinal density. This NF was tested in HIV-infected
cell lines, and outcomes were similar to those obtained in
normal cell lines. In future, efforts must be made toward
the encapsulation of NCs, anti-HIV drugs, and antagonists
against substances of abuse to develop an effective NF. Such
developed NFs would be capable of eradicating HIV infection
and to block the effects induced by substances of abuse in
HIV patients. The state-of-the-art and possible future strategy
to eradicate and manage HIV is shown in Figure 2.
Nanoengineered NCs, highly sensitive technologies, and
smart assays are being explored to develop an ideal nanomedicine via improving properties of NCs, pharmacokinetics,
and acceptable neurobehavioral alteration.34 During virus
progression, the dysfunction of related biomarkers and genes
has been quantified using sensitive analytical assays, namely,
polymerase chain reaction, and enzyme-linked immunosorbent assay. Ultrasensitive histopathology, immunohistopathology, and optical fluorescence imaging have been adopted
recently to explore the biodistribution, pathogenesis, and
toxicity of both NCs and NFs. Recently, transmission electron microscopy (Figure 1) with illuminating features was
introduced to study the distribution of NCs in various organs
to explain particle-to-particle interaction and elemental
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Figure 2 State-of-the-art personalized nanomedicine to cure HIV and neuroAIDS.
Abbreviations: HIV, human immunodeficiency virus; neuroAIDS, neuroacquired immunodeficiency syndrome; BBB, blood–brain barrier.

composition of NCs over time after injection.20 Biodistribution and therapeutic effects of contrast agents containing NCs
and NFs in the periphery and brain were studied using magnetic resonance imaging. The homeostatic effect of NCs in
the living system was also studied using magnetic resonance
imaging via real-time monitoring of contrast exposure.
It has been reported that HIV infection is serious, but it
turns worst in combination with drugs of abuse. For example,
HIV patients due to life style and ingestion of drug of abuse
were found to be psychologically stressed which resulted
in delayed response to therapeutics.35 Thus, stress monitoring in HIV patients is crucial to decide therapeutics. Stress
management of HIV patients has been declared necessary
to obtain information for clinicians to avoid delay in therapeutics.35 The addition of such analytical devices is new to
HIV therapy, but clinicians expect bright future prospects to
assess social assessment impact of patients.36 The introduction of analytical sensing systems for HIV incidence will
be of great significance.36,37 Enzyme-linked immunosorbent
assay and real-time/quantitative polymerase chain reaction
have demonstrated estimation of potential HIV biomarkers
such as HIV-1 RNA viral load and CD4 cell counts. These
methods have also quantified other HIV-infection-related
biomarkers such as serum concentration of neopterin, beta-2
microglobulin (IgA), interleukin-2 receptor, CD8 cell counts,
anti-HIV antibodies, p24 antigen, hemoglobin level, platelet
concentration, and erythrocyte sedimentation rate. Both
these methods are very well established, but the need for
high operation expertise and longer analysis time has raised
the demand for rapid diagnostic tools to detect/monitor HIV
infection in the physiological range. The available detection
4322

Powered by TCPDF (www.tcpdf.org)

submit your manuscript | www.dovepress.com

Dovepress

tools for detection of HIV biomarkers with performance
parameters are summarized in Table 1.
Recently, electrochemical biosensing system has been
developed to detect physiological stress markers in HIV
patients. The electrochemical biosensors recently emerged as
a potential analytical tool to detect target biomarkers at the
picomolar level.38–41 Shafiee et al have described the available
potential techniques to detect HIV biomarkers to estimate HIV
infection level. This group also proposed that the development of electrochemical system with features of affordability,
sensitivity, specificity, user friendliness, rapidity, robustness,
equipment-freeness, and desirability can be promoted at pointof-care application to detect HIV infection for personalized
health care.36 The performance of available detection tools to
detect and monitor HIV infection is summarized in Table 2.
As per state of the art and according to ASSURED,
a biosensor fabricated using a nanoplasmonic resonance
detected ~100 copies/mL of HIV-1 subtype D using a
very small volume (100 µL) of whole blood and plasma.42
A label-free optical biosensor developed using a nanophotonic
crystal was used to detect 104–106 copies/mL of HIV-1 in blood
plasma.43 Such nanoenabled biosensors were operated simply
with the salient feature of integration with nanosensing components such as nanoelectronics, miniaturized transduction
techniques, and microelectromechanical systems for detection
of potential HIV-infection biomarkers (CD+ T lymphocytes
and viral load) in the real sample, even at the point-of-care
application.44–46 Using lab-on-chip-based approach, the
capturing and quantification of CD+ lymphocytes has been
demonstrated by Watkins et al.47 The authors reported that
lab-on-chip functionalized by a specific antibody detected
International Journal of Nanomedicine 2016:11
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Table 1 Available analytical tools for detection of HIV infection
Techniques

CD+ T lymphocytes
counting

Flow cytometry

Conventionally well established
for both

Image processing

Bright field or fluorescent
image of CD+ T lymphocytes

ELISA

Centrifuge-based approach

RT-PCR

Electrical sensing

Viral load
estimation

Remarks

Nanoenabled ELISA

DNA based
virus capture based

•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•

Best suitable for HIV detection
and monitoring

Assay time: 8–40 minutes
Sample volume: 10 µL of blood
Laboratory set-up
Not suitable for POC
Assay time: 20–30 minutes
Sample volume: 30 mL of whole blood
Power: AC battery
Only qualitative
Not suitable for POC
Assay time: 40 minutes for CD+ and 48 hours for viral load
Sample volume: 30 µL of blood and 1 mL of plasma
Power: DC battery
Assay time: 35–90 minutes
Sample volume: 150 µL of blood, 75 µL of fingerstick
blood, and 1 mL of plasma
Power: AC/DC battery
Sensing time: 15–30 minutes
Sample volume: 10 µL
Power: AC battery/solar
Sensitive and selective
Suitable for detection and monitoring
Suitable for POC application

Abbreviations: HIV, human immunodeficiency virus; POC, point of care; AC, alternating current; ELISA, enzyme-linked immunosorbent assay; DC, direct current;
RT-PCR, reverse transcription polymerase chain reaction.

viral lysate ranging from 100 cells/mL to 700 cells/mL,
with a detection limit of 9 cells/µL and a detection range
from 100 cells/mL to 700 cells/µL.47 However, the detection of neuroHIV infection and also HIV incidences was not
well explored by these sensing systems. Significant efforts

should be made to investigate biomarkers for the detection of
neuroHIV infection. The significance of neuroHIV monitoring
and management using advanced nanoenabling sensing systems is described by Nair et al,1 as shown in Figure 3. Recently,
electrochemical monitoring of HIV-infection in presence

Table 2 A performance summary of available diagnostic tests/tools used to detect HIV infection
Diagnostic test/tool
Low-cost, rapid HIV-monitoring tests:
• OraQuick Rapid HIV-1/2 Antibody Test
• Aware HIV-1/2 U (alternative to urine tests)
• Anti-HIV antibody and p24 antigen (for early infant diagnosis and for HIV-1 and
HIV-2 subtype differentiation)
• HIV-1/2 Ag/Ab Combo (antigen and antibody)
HIV viral load monitoring:
• RT assay: (ExaVir Load)
• NAT: i) COBAS Amplicor HIV-1 Monitor v1.5; ii) COBAS AmpliPrep/COBAS
TaqMan v2.0; iii) Real-Time HIV-1; and iv) VERSANT HIV-1 RNA 1.0 Assay (kPCR)
• Non-NAT (HIV viral enzymes and proteins)
• p24 antigen technologies (NEN HIV-1 p24 ELISA)
• p24 antigen + anti-HIV, IgM, and IgG antibodies (HIV-1/2Ag/Ab Combo)

Detection technique and sensitivity/specificity
• Oral fluids/blood sample (92.7%/100%)
• Blood/serum (88.7%/99.9%)
• ELISAs (12.5–200 pg/mL)
• Immunochromatographic (50%/86%)
•
•
•
•
•

RT activity in blood 200–600,000 copies/mL
Detect and quantify viral RNA via RT-PCR
50–750,000 copies/mL with 99.85% specificity
N/A
Detect and quantify HIV viral enzymes and proteins
(10,000–30,000 RNA copies/mL)
• Detect blood p24 antigen (30,000–50,000 RNA copies/mL)

Microfluidics diagnostic:
• p24 test for EID
• CD4+ cells from whole blood (Daktari Diagnostics)

• Plasma (95%/99%)
• Whole blood (97%/86%)

POC:
• Ultrasensitive p24 Antigen Assay (NWGHF)
• PanNAT Diagnostic Platform
• Portable CD4+ T-cell count (PointCare NOW, CyFlow miniPOC)

• Heel-stick blood (95%/99%)
• Blood (95%/99%)
• Blood (90%/96%)

Abbreviations: HIV, human immunodeficiency virus; ELISA, enzyme-linked immunosorbent assay; RT, reverse transcription; NAT, nucleic acid-based tests; PCR, polymerase
chain reaction; N/A, not applicable; EID, early infant diagnosis; POC, point of care.
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9'UXJUHVLVWDQFH
90RWKHUWRFKLOGWUDQVPLVVLRQ
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96RPHWLPHH[KLELWVFHOOGDPDJH
91HHGWRGHYHORSQRYHOELRFRPSDWLEOH
PXOWLIXQFWLRQDOLPDJLQJDJHQWV

91HHGWRRSWLPL]HGHYLFHLQWHJUDWLRQZLWKUHGXFHG
IRUPIDFWRUV

Figure 3 Performance comparison of analytical tools used to monitor and detect neuroHIV/AIDS.
Note: Reprinted from Adv Drug Deliv Rev, 103/1, Nair M, Jayant RD, Kaushik A, Sagar V, Getting into the brain: potential of nanotechnology in the management of
neuroAIDS, 202–217, Copyright (2016), with permission from Elsevier.1
Abbreviations: ARV, antiretroviral; neuroHIV, neurohuman immunodeficiency virus; AIDS, acquired immunodeficiency syndrome; BBB, blood–brain barrier; POC, point of care.

of cocaine and specific drugs related with HIV-infection
and cocaine was demonstrated using an elctrochemical
monitoring-on-chip (E-Moc) approach. Authors developed a
cultureware chip and human astrocytes based in-vitro model
for HIV-infection, Cocaine explore, treatment with Tef, along
with rimcazole (RA, a cocaine antagonist). Electrochemical
impedance spectroscopy was performed to evaluate electrophysiology of cells during infection and therapeutic. Author
claimed this methodology as an effective analytical tool for
HIV-infection monitoring in various conditions.48
In summary, to cure HIV and neuroHIV/AIDS, we
believe that significant research must be performed to design
novel biocompatible NFs with salient features of target site
delivery, novel easy mechanism to release ARV drugs, and
effective CNS delivery to eradicate latent HIV infection. The
investigation of novel diagnostic tools for detection of infection and its integration with NF-based HIV eradication will
be useful to assess NF functionality with real-time monitoring
of HIV infection. These significant advancements will help to
decide HIV therapeutics and management. Therefore, we can
say that involvement of new analytical diagnostic tools and
nanoenabling formulations will simplify both HIV diagnosis
and cure to manage personalized care.
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